Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.55 USD
Change Today -0.04 / -2.52%
Volume 41.4K
PIP On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 6:40 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

pharmathene inc (PIP) Snapshot

Open
$1.57
Previous Close
$1.59
Day High
$1.63
Day Low
$1.55
52 Week High
09/10/14 - $2.59
52 Week Low
07/23/14 - $1.19
Market Cap
98.7M
Average Volume 10 Days
57.4K
EPS TTM
$-0.18
Shares Outstanding
63.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMATHENE INC (PIP)

pharmathene inc (PIP) Related Businessweek News

No Related Businessweek News Found

pharmathene inc (PIP) Details

PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the Biomedical Advanced Research and Development Authority, Chemical Biological Medical Systems, and the National Institute of Allergy and Infectious Diseases. It has collaboration with Bristol-Myers Squibb for developing Valortim; and strategic alliance with Nanotherapeutics, Inc. to develop biodefense programs. The company is headquartered in Annapolis, Maryland.

35 Employees
Last Reported Date: 03/11/15

pharmathene inc (PIP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmathene inc (PIP) Key Developments

PharmAthene, Inc. Announces Executive Changes

PharmAthene, Inc. announced that, in connection with the realignment plan, it plans to reduce its staffing levels by approximately two thirds. Eric Richman, President and Chief Executive Officer, will remain a member of the Board of Directors, but will no longer serve as an Officer of the company after March 11, 2015. He will continue to play a key role in managing the ongoing litigation, other legal matters and strategic transactions in his role as Director. Linda Chang will continue to serve as Chief Financial Officer through April 30, 2015. In accordance with meeting cost-saving objectives, the board will be reduced from eight members to six and Messrs. Joel McCleary and Brian A. Markison intend to resign from the board. John M. Gill, a Director of the company for the past nine years, will assume the role of President and Chief Executive Officer. Mr. Gill is a seasoned biotech executive with more than 30 years' experience in corporate development and strategic planning. Previously, he served as Co-Founder and Chief Executive Officer of TetraLogic Pharmaceuticals and Chief Operating Officer of 3-Dimensional Pharmaceuticals until its sale to Johnson & Johnson. Current Vice President and Controller, Philip MacNeill, will become the Chief Financial Officer following the departure of Linda Chang. Mr. Gill is expected to devote necessary time to carry out his duties as President and Chief Executive Officer, and although he does not have other employment, he is not expected to devote his full time to the business of the company, which his compensation will reflect.

PharmAthene, Inc. Announces Consolidated Earnings Results for the Year Ended December 31, 2014

PharmAthene, Inc. announced consolidated earnings results for the year ended December 31, 2014. For the year, the company reported contract revenue of $10,190,205 against $17,912,607 a year ago. Loss from operations was $10,191,305 against $10,839,208 a year ago. Loss before income taxes was $9,893,649 against $11,656,607 a year ago. Net loss was $9,955,395 or $0.17 basic and diluted per share against $11,718,353 or $0.23 basic and diluted per share a year ago. The decrease in revenue in 2014 is primarily attributable to a reduction in activity in the company's SparVax and rBChE bioscavenger programs during 2014, due to the de-scoping and partial termination for convenience of the SparVax contract and expiration of the bioscavenger contract.

PharmAthene Seek Partners

PharmAthene, Inc. (AMEX:PIP) seeks partners, co-developers or acquirers for its other biodefense programs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIP:US $1.55 USD -0.04

PIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $68.91 USD -0.74
Bayer AG €126.66 EUR +0.46
Protalix BioTherapeutics Inc 808.30 -21.90
View Industry Companies
 

Industry Analysis

PIP

Industry Average

Valuation PIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.9x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMATHENE INC, please visit www.pharmathene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.